DRIO vs HIMS

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -17. 3% for DarioHealth Corp. (DRIO). DarioHealth Corp. (DRIO) offers the better valuation at 6. 6x trailing P/E, making it the more compelling value choice. Analysts rate DarioHealth Corp. (DRIO) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, DarioHealth Corp.

(DRIO) is the cheapest at 6. 6x versus Hims & Hers Health, Inc. at 50. 3x.

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +137. 6%, compared to -97. 8% for DarioHealth Corp. (DRIO). Over 10 years, the gap is even starker: HIMS returned +161. 9% versus DRIO's -99. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), DarioHealth Corp.

(DRIO) is the lower-risk stock at 0. 26β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately 810% more volatile than DRIO relative to the S&P 500. On balance sheet safety, DarioHealth Corp. (DRIO) carries a lower debt/equity ratio of 47% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus -17. 3% for DarioHealth Corp. (DRIO). On earnings-per-share growth, the picture is similar: DarioHealth Corp. grew EPS 267. 6% year-over-year, compared to -3. 8% for Hims & Hers Health, Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

DarioHealth Corp.

(DRIO) is the more profitable company, earning 276. 1% net margin versus 5. 5% for Hims & Hers Health, Inc. — meaning it keeps 276. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HIMS leads at 5. 2% versus -163. 9% for DRIO. At the gross margin level — before operating expenses — HIMS leads at 59. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for DRIO: 96.

9% to $16. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, DarioHealth Corp.

(DRIO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 26)). Hims & Hers Health, Inc. (HIMS) carries a higher beta of 2. 40 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DRIO: -99. 6%, HIMS: +161. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: DRIO is a small-cap deep-value stock; HIMS is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.